Sharekhan's research report on Gland Pharma
Gland is an established player in Injectables space and is well-placed to harness the growth opportunities in this space. It has a strong compliance record with nil observations from the USFDA across all its plants. Gland has a unique B2B business model, which enables it grow its market share while maintaining cost leadership. Strong domain expertise, robust growth prospects, sturdy & consistent earnings track record, and healthy return ratios make Gland an ideal long-term investment pick.
Outlook
We Initiate coverage on Gland Pharma Limited (Gland) with a Buy recommendation and a price target of Rs. 3,040.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
